Hims & Hers is facing regulatory hurdles that forced the removal of a competitive $49 weight loss pill, potentially easing pricing pressure on Novo Nordisk's offerings.
Source Post
Why Is Novo Nordisk Stock Crashing, and is it a Buying Opportunity? | #novonordisk #novo #stocks #ai
Mar 2, 2026
Parkev Tatevosian, CFA, analyzes the recent downturn in Novo Nordisk stock, noting that while the company has faced decelerating revenue growth and declining returns on invested capital since 2015, it remains a strong long-term play. The analysis highlights competitive pressures from 'compounders' like Hims & Hers, though recent regulatory actions have forced the removal of some low-cost generic alternatives from the market. Despite market share concerns and a battle with Eli Lilly in the weight loss sector, a proprietary discounted cash flow model suggests Novo Nordisk is undervalued at $49, with a calculated fair value of $62 per share.
Linked Mentions
Tickers discussed in this post
Novo Nordisk is rated as a buy with a $62 fair value target, supported by a DCF model and the massive growth potential of the obesity care market despite recent ROIC declines.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.